Vertex Pharmaceuticals (VRTX) Short-term Investments (2009 - 2026)

Vertex Pharmaceuticals has reported Short-term Investments for 18 years, with the latest figure at $1.7 billion in Q2 2026.

• On a quarterly basis, Short-term Investments rose 21.15% year-over-year to $1.7 billion in Q2 2026; TTM through Jun 2026 was $1.7 billion, a 21.15% increase from a year earlier, with the FY2025 full-year figure at $1.5 billion, down 1.49% from the prior year.
• Short-term Investments was $1.7 billion for Q2 2026 at Vertex Pharmaceuticals, down from $1.8 billion in the prior quarter.
• The five-year high for Short-term Investments was $1.8 billion in Q1 2026, with the low at $274.5 million in Q4 2022.
• Average Short-term Investments over 5 years is $1.1 billion, with a median of $1.2 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments tumbled 62.39% in 2022, then jumped 209.36% in 2023.
• Over 5 years, Short-term Investments stood at $274.5 million in 2022, then surged by 209.36% to $849.2 million in 2023, then soared by 82.09% to $1.5 billion in 2024, then slipped by 1.49% to $1.5 billion in 2025, then rose by 12.18% to $1.7 billion in 2026.
• The last three Short-term Investments figures came in at $1.7 billion (Q2 2026), $1.8 billion (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.